Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1971-1980 of 11532

Edit search filters
  1. Study Of HPN536 In Patients With Advanced Cancers Associated With Mesothelin Expression

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. A Novel Vaccine (EO2463) As Monotherapy And In Combination, For Treatment Of Patients With Indolent Non-Hodgkin Lymphoma

    Rochester, MN

  3. A Study To Evaluate The Safety And Efficacy Of A2B530, A Logic-gated CAR T, In Subjects With Solid Tumors That Express CEA And Have Lost HLA-A*02 Expression

    Jacksonville, FL, Rochester, MN

  4. A Study To See If Tolvaptan Is Safe In Infants And Children Who At Enrollment Are 28 Days To Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

    Rochester, MN

  5. Study Of DF9001 In Patients With Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  6. Testing The Role Of FDG-PET/CT To Predict Response To Therapy Prior To Surgery For HER2-positive Breast Cancer, The DIRECT Trial

    Eau Claire, WI, Jacksonville, FL, La Crosse, WI, Rochester, MN

  7. STOP-HER2: Stopping Trastuzumab In HER2+ MBC

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. Pilot Study Of Care At Home For Monitoring Brain Tumor Patients

    Rochester, MN

  9. IDE196 (Darovasertib) In Combination With Crizotinib As First-line Therapy In Metastatic Uveal Melanoma

    Rochester, MN

  10. Expanded Access Study For The Treatment Of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

    Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer